Company intelligence / Profile preview
Veralox Therapeutics
Frederick, Maryland, United Statesveralox.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
VLX-1005 has completed two Phase 1 studies in 96 healthy participants showing favorable safety and tolerability with no deaths, no serious adverse events, and no trend in AE reporting with increased dosing. A Phase 2 study (VLX-1005-003) to evaluate VLX-1005 in patients with suspected HIT is currently enrolling patients across 14 clinical sites[5].
- Therapeutic areas
- HematologyEndocrinologyImmunology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Exclusive agreement with Nudge Therapeutics
Beyond the preview
Go deeper on Veralox Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Veralox Therapeutics.